British Journal of Dermatology

Papers
(The H4-Index of British Journal of Dermatology is 44. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-04-01 to 2024-04-01.)
ArticleCitations
Classification of the cutaneous manifestations of COVID ‐19: a rapid prospective nationwide consensus study in Spain with 375 cases922
SARS‐CoV‐2 endothelial infection causes COVID‐19 chilblains: histopathological, immunohistochemical and ultrastructural study of seven paediatric cases335
Tralokinumab for moderate‐to‐severe atopic dermatitis: results from two 52‐week, randomized, double‐blind, multicentre, placebo‐controlled phase III trials (ECZTRA 1 and ECZTRA 2)*269
The global burden of atopic dermatitis: lessons from the Global Burden of Disease Study 1990–2017*199
Further characterization of clinical and laboratory features in VEXAS syndrome: large‐scale analysis of a multicentre case series of 116 French patients*173
Monkeypox outbreak in Spain: clinical and epidemiological findings in a prospective cross-sectional study of 185 cases173
Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial163
Cutaneous reactions after SARS-CoV-2 vaccination: a cross-sectional Spanish nationwide study of 405 cases157
Cutaneous manifestations in patients with COVID‐19: a preliminary review of an emerging issue157
The global burden of chronic urticaria for the patient and society*148
Adverse skin reactions among healthcare workers during the coronavirus disease 2019 outbreak: a survey in Wuhan and its surrounding regions132
British Association of Dermatologists guidelines for biologic therapy for psoriasis 2020: a rapid update123
Role of regulatory T cells in psoriasis pathogenesis and treatment119
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical115
The epidemiology of hidradenitis suppurativa*99
Aetiology and pathogenesis of hidradenitis suppurativa91
The impact of the COVID ‐19 pandemic on patients with chronic plaque psoriasis being treated with biological therapy: the Northern Italy experience90
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)85
Evidence for a ‘window of opportunity’ in hidradenitis suppurativa treated with adalimumab: a retrospective, real‐life multicentre cohort study*83
The differing pathophysiologies that underlie COVID‐19‐associated perniosis and thrombotic retiform purpura: a case series73
Efficacy and safety of ixekizumab in a phase III , randomized, double‐blind, placebo‐controlled study in paediatric patients with moderate‐to‐severe plaque psoriasis73
Co‐reactivation of the human herpesvirus alpha subfamily (herpes simplex virus‐1 and varicella zoster virus) in a critically ill patient with COVID‐1973
Reviewing the global burden of acne: how could we improve care to reduce the burden?*67
Absence of images of skin of colour in publications of COVID‐19 skin manifestations66
Systematic review examining changes over time and variation in the incidence and prevalence of psoriasis by age and gender*66
Cutaneous lesions in a patient with COVID‐19: are they related?60
Most chilblains observed during the COVID‐19 outbreak occur in patients who are negative for COVID‐19 on polymerase chain reaction and serology testing*60
British Association of Dermatologists guidelines for the management of people with cutaneous squamous cell carcinoma 2020*59
Exploring the human hair follicle microbiome*57
Prevalence of mucocutaneous manifestations in 666 patients with COVID‐19 in a field hospital in Spain: oral and palmoplantar findings56
Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVID‐19 pandemic56
Five‐year efficacy and safety of tildrakizumab in patients with moderate‐to‐severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURF55
Incidence, prevalence and mortality of bullous pemphigoid in England 1998–2017: a population‐based cohort study*55
Emergency management for preventing and controlling nosocomial infection of the 2019 novel coronavirus: implications for the dermatology department55
British Association of Dermatologists guidelines for the management of adults with basal cell carcinoma 2021*54
Comparing the efficacy and tolerability of biologic therapies in psoriasis: an updated network meta‐analysis53
A head‐to‐head comparison of ixekizumab vs. guselkumab in patients with moderate‐to‐severe plaque psoriasis: 24‐week efficacy and safety results from a randomized, double‐blinded trial*53
COVID‐19 chilblain‐like lesion: immunohistochemical demonstration of SARS‐CoV‐2 spike protein in blood vessel endothelium and sweat gland epithelium in a polymerase chain reaction‐negative patient53
Putting the burden of skin diseases on the global map50
Ustekinumab for the treatment of moderate‐to‐severe plaque psoriasis in paediatric patients (≥ 6 to < 12 years of age): efficacy, safety, pharmacokinetic and biomarker results from the open‐label 50
Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting*47
Applications and future directions for optical coherence tomography in dermatology*46
Dupilumab provides favourable long‐term safety and efficacy in children aged ≥ 6 to < 12 years with uncontrolled severe atopic dermatitis: results from an open‐label phase IIa study and subsequent 45
Janus kinase 1 inhibitor INCB054707 for patients with moderate‐to‐severe hidradenitis suppurativa: results from two phase II studi44
0.033125877380371